Pangea Natural Food, Inc. AI Stock Analysis
Want to see TSE:BPC full AI Analyst Report?
Pangea Natural Food, Inc. (BPC) AI Stock Analysis
Pangea Natural Food, Inc.
(CNQX:BPC)
Overall score is driven primarily by weak financial performance (deep losses, negative margins, and accelerating cash burn) and a bearish technical trend (price below key moving averages with negative MACD). Valuation is also constrained by negative earnings (negative P/E) with no dividend yield data to offset the risk.
Pangea Natural Food, Inc. (BPC) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 13.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 130.76K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 0.45
- Revenue Growth
- 2292.02%
- EPS Growth
- -62.06%
- Country
- Canada
- Employees
- 2
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Restaurants
Pangea Natural Food, Inc. Business Overview & Revenue Model
Company Description
The Precision Peptide Company Inc. manufactures and distributes plant-based patties and other food products in Canada. The company offers old fashioned ghee; energy gel; and plant-based patty; energy gel products, and munchie mix, as well as custom c...
Pangea Natural Food, Inc. Financial Statement Overview
Summary
Financial profile is weak: profitability is persistently negative with a very large 2025 gross loss (gross margin -139.1%) and a deeply negative net margin (-91.0%). Cash flow is consistently negative and deteriorated in 2025 (operating cash flow -2.33M), indicating ongoing cash burn. Balance sheet leverage is low, but equity has been unstable (negative in 2023–2024), which raises financing/dilution risk if losses continue.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
10Very Negative| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.72K | 49.72K | 12.20K | 285.59K | 580.99K | 68.50K |
| Gross Profit | -24.28K | -69.17K | 6,905 | -32.79K | 40.97K | -67.25K |
| EBITDA | -2.16M | -2.16M | -917.21K | -1.64M | -855.30K | -172.28K |
| Net Income | -4.58M | -4.53M | -1.03M | -1.66M | -1.13M | -173.19K |
Balance Sheet | ||||||
| Total Assets | 1.33M | 1.33M | 182.29K | 191.72K | 620.34K | 1.34M |
| Cash, Cash Equivalents and Short-Term Investments | 960.01K | 960.01K | 140.09K | 51.64K | 75.95K | 807.57K |
| Total Debt | 0 | 0 | 17.83K | 0 | 0 | 0 |
| Total Liabilities | 401.26K | 401.26K | 732.74K | 330.00K | 408.57K | 116.82K |
| Stockholders Equity | 929.72K | 929.72K | -550.45K | -138.28K | 211.76K | 1.23M |
Cash Flow | ||||||
| Free Cash Flow | -1.95M | -2.33M | -439.41K | -980.68K | -725.80K | -590.75K |
| Operating Cash Flow | -1.95M | -2.33M | -439.41K | -980.68K | -718.60K | -529.76K |
| Investing Cash Flow | -573.83K | -270.17K | 0 | 0 | -7,200 | -60.98K |
| Financing Cash Flow | 3.32M | 3.40M | 527.86K | 956.37K | -1,320 | 1.40M |
Pangea Natural Food, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BPC, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.37, and below the 200-day MA of 0.40, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.47 is Neutral, neither overbought nor oversold. The STOCH value of 35.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BPC.
Pangea Natural Food, Inc. Peers Comparison
Overall Rating
TSE:MEAT46Neutral
TSE:NPRA44Neutral- TSE:BPC40Underperform
TSE:ISTK24.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| TSE:MEAT | 46Neutral | CAD 220.55K | -0.34 | 30.06% | ― | -3.70% | 51.27% |
| TSE:NPRA | 44Neutral | CAD 42.88M | -30.09 | 30.14% | ― | 32.91% | 55.73% |
| TSE:BPC | 40Underperform | CAD 13.35M | -2.02 | -161.83% | ― | 2292.02% | -62.06% |
| TSE:ISTK | 25Underperform | CAD 37.81M | -24.03 | 81.87% | ― | ― | ― |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BPC | Pangea Natural Food, Inc. | 0.29 | -0.04 | -12.12% | |
| TSE:ISTK | Good Flour Corp | 0.30 | -2.50 | -89.29% | |
| TSE:MEAT | Modern Plant Based Foods Inc. | 0.03 | -0.16 | -84.21% | |
| TSE:NPRA | Nepra Foods, Inc. | 0.34 | 0.21 | 161.54% |
Pangea Natural Food, Inc. Corporate Events
Precision Peptide Adds Six Peptides Under New U.S. Policy
PositiveThe Precision Peptide Company is a publicly traded wellness company focused on advanced peptide formulations and delivery systems. Its U.S. prescription platform combines online health assessments, clinician review, U.S. 503A pharmacy compounding and...
HHS Draft Policy Supports Precision Peptide’s Needle-Free Strategy
PositiveThe Precision Peptide Company is a publicly traded wellness company focused on advanced peptide formulations and delivery systems, with a U.S. market strategy spanning needle-free patches, oral and topical products, and clinician-prescribed therapies...
Precision Peptide Company Quadruples U.S. Telehealth Peptide Formulary
PositiveThe Precision Peptide Company has rapidly expanded its U.S. telehealth formulary from four to 16 prescription therapies across seven wellness areas in less than four months since its nationwide telehealth launch. The portfolio now comprises 23 produc...
Precision Peptide Company Leans on 30 Years of Science to Differentiate Peptide Wellness Platform
PositiveThe Precision Peptide Company is emphasizing the scientific depth behind its peptide-based wellness platform, highlighting Chief Scientific Officer and co-founder Justin Kirkland, whose three decades of peptide synthesis, analytical chemistry and for...
Precision Peptide Secures Exclusive U.S. Manufacturing for Needle-Free Patch Line
PositivePrecision Peptide Company has secured exclusive manufacturing rights for all four peptide patch formulations, including BPC-157, Thymosin Alpha-1, tirzepatide and GLP3. Each patch will be produced solely by a single U.S. manufacturer, with the Recove...
Precision Peptide Company Adds GLP3 Patch to U.S.-Made Needle-Free Peptide Line
PositiveThe Precision Peptide Company has expanded its needle-free peptide portfolio by starting development of a GLP3 transdermal patch in the U.S., its fourth patch and second targeting metabolic and weight-management applications. The company already sell...
Precision Peptide Advances Needle-Free Tirzepatide Patch Into U.S. Testing
PositiveThe Precision Peptide Company has moved its needle-free tirzepatide GLP-1 transdermal patch into formal testing in the United States, marking the third product to advance through its transdermal development pipeline. Designed to deliver tirzepatide w...
Precision Peptide Orders First Commercial Run of Thymosin Alpha-1 Patch
PositiveThe Precision Peptide Company has ordered 20,000 units of its needle-free Thymosin Alpha-1 transdermal patch ahead of a planned commercial launch. Each U.S.-manufactured patch is formulated to deliver 2 mg of the immune-modulating peptide, moving the...
Precision Peptide Company Opens U.S. Wholesale Channel for Needle-Free Wellness Products
PositiveThe Precision Peptide Company has launched a U.S. wholesale program for its non-prescription, needle-free patches and supplements, opening distribution to gyms, fight academies, longevity clinics, med spas, physio and chiropractic practices, and spec...
Precision Peptide Company Sponsors Mental Health Boxing Event to Expand Combat Sports Reach
PositiveThe Precision Peptide Company has become a strategic sponsor of Championing Mental Health 3, a professional boxing event promoted by Bash Boxing and scheduled for September 26, 2026, at Commerce Casino in California. The event will be broadcast on UF...
Precision Peptide Company Advances Thymosin Alpha-1 Patch in U.S. Testing
PositiveThe Precision Peptide Company has advanced its Thymosin Alpha-1 transdermal patch into formal testing in the United States, aiming to complete the program by the second half of 2026 and move toward commercial production if results are satisfactory. T...
Precision Peptide Company Grants RSUs and Stock Options to Consultant
PositiveThe Precision Peptide Company Inc. has authorized the grant of 150,000 restricted share units and 200,000 incentive stock options to a company consultant under its omnibus share incentive plan. Each option allows the purchase of one common share at a...
Precision Peptide Expands U.S. Rollout With FitExpo Anaheim Showcase
PositiveThe Precision Peptide Company will showcase and sell its supplement range at FitExpo Anaheim on August 29–30, 2026, marking a step in its transition from purely online direct-to-consumer sales to live retail engagement with fitness and wellness enthu...
Precision Peptide Plans Needle-Free Tirzepatide Patch for Expanding GLP-1 Market
PositiveThe Precision Peptide Company Inc. announced it is developing a tirzepatide-based transdermal patch in the U.S. as an addition to its peptide-focused product portfolio. The patch is designed to deliver the dual GIP/GLP-1 agonist through the skin, off...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026